PNLIP and colorectal cancer: Additionally, PTL modifies the interactions between C (CAFs) and tumor cells, diminishing CAFs' tumor‐promoting effects.[35] Its compatibility with the CMD‐BHQ3 system further enhances bioavailability and controlled release, optimizing tumor‐targeted delivery and minimizing adverse effects.[37, 38] Thus, PTL stands out as a promising candidate for colorectal cancer therapy, combining stemness inhibition with innovative delivery strategies.